BWA
MDGL icon

Basecamp Wealth Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Basecamp Wealth Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Buy
28
+1
+4% +$512 ﹤0.01% 906
2026
Q1 		$14.1K Sell
27
-16
-37% -$7.64K ﹤0.01% 927
2025
Q4 		$25K Buy
+43
New +$22K 0.01% 718

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Basecamp Wealth Advisors's MDGL Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 3.7% in Q2 2026, buying an estimated $512 and bringing the position to 28 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

Basecamp Wealth Advisors first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $25K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Basecamp Wealth Advisors held 28 shares of Madrigal Pharmaceuticals worth $15K as of Q2 2026.
  • Basecamp Wealth Advisors bought 1 Madrigal Pharmaceuticals share in Q2 2026, an estimated $512.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #906 holding.
  • Basecamp Wealth Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Madrigal Pharmaceuticals position peaked at $25K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.